Triple
T6003734
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Loxo Oncology |
E133655
|
entity |
| Predicate | secondMajorProductAlsoKnownAs |
P68641
|
FINISHED |
| Object | LOXO-292 |
E561037
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: LOXO-292 | Statement: [Loxo Oncology, secondMajorProductAlsoKnownAs, LOXO-292]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: LOXO-292 Context triple: [Loxo Oncology, secondMajorProductAlsoKnownAs, LOXO-292]
-
A.
LOXO-292
chosen
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
B.
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
C.
LOXO-305
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
-
D.
LOXO
LOXO was the stock ticker symbol for Loxo Oncology, a biopharmaceutical company focused on developing targeted cancer therapies before its acquisition.
-
E.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: secondMajorProductAlsoKnownAs Context triple: [Loxo Oncology, secondMajorProductAlsoKnownAs, LOXO-292]
-
A.
secondaryProducts
Indicates that certain entities arise as secondary or byproduct outputs from a primary process, activity, or production.
-
B.
secondaryBrand
Indicates that one brand is a subordinate, supporting, or less prominent brand in relation to a primary brand.
-
C.
primaryProduct
Indicates that one entity is the main or most important product associated with, produced by, or offered by another entity.
-
D.
laterProductType
Indicates that one product type occurs or is introduced after another product type in time or sequence.
-
E.
secondaryTo
Indicates that one condition, event, or factor occurs as a consequence of, or is caused by, another primary condition, event, or factor.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00872444c8190bfaf1739dcec765c |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04f0f63148190826198281dce3713 |
completed | March 22, 2026, 8:20 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c13564c2088190847cde0b9ec02591 |
completed | March 23, 2026, 12:43 p.m. |
| PD | Predicate disambiguation | batch_69c049e3316c819087ea635fa7ee8472 |
completed | March 22, 2026, 7:58 p.m. |
| PDg | Predicate description generation | batch_69c04e8c5bfc8190b986a7071d1b23e3 |
completed | March 22, 2026, 8:18 p.m. |
Created at: March 22, 2026, 4:06 p.m.